Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
about
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation.The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinomaThe new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.The molecular genomics of metastatic brain tumours.Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancerItalian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practiceCost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR InhibitorsGefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitorsRisk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutationGreater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasisPersonalizing therapy in advanced non-small cell lung cancerAnalysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasisTargeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerEGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancerComparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review.Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis.The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancerEpidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer.Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapy.EGFR mutation testing practice in advanced non-small cell lung cancer.Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.
P2860
Q33706859-39404277-9F16-4BB3-9798-A5CBF67BE956Q33881082-D25EDB68-5F0F-42A6-B6E3-05D4C98B9583Q33995206-7A9390D6-E63A-4DF9-9F91-EF5F6E17FC15Q34404266-42524BB3-D41F-49F4-9054-4286298FB3FFQ34499855-60CD5836-4BB0-4018-8E91-7DB01FE21861Q34772704-12842E6B-0B64-4B7D-BE81-CC96C73240B0Q35123203-82BA5C30-15B8-4E57-AA10-B478D15DF44FQ35200569-D06A30EB-1B8F-4C5A-A993-60B1DCFC2011Q35394529-25A4E085-0DE0-4272-A9DE-4188E60B6B7CQ35820508-22C3028E-9064-41F4-B2F1-0EB2864B5BABQ36095128-296CA5AB-C9BA-4E19-A709-823D0595DC46Q36116376-BE6358F2-E869-4F26-9C49-12E06F24FB02Q36334253-71187586-2C74-4338-A97B-B8DC8AC41E68Q36540405-5185C0BD-FFEC-435F-AD43-D09420357CCFQ36575287-EDEC2C07-6453-4517-AF79-02B32227E560Q36772230-21DF5277-B44A-47B5-AE2E-8C8EF6807EB4Q36811453-44C1B7F2-BB6C-4D85-AFD8-B0162ADD08B5Q37119867-0DD6094C-C2F3-47A8-B888-FCEEF350D340Q37246286-5A3DF575-CABD-4B26-8429-B206AF8EB8A0Q37592893-EC3B1B08-B7BB-4E26-8D6E-51245EDBD1C7Q37637905-D030ADE6-F4B4-42E0-95B1-B4EA57E21FA4Q37639588-FCFA96AC-9AC1-4B33-A100-BC97A0DCD193Q37670436-2055CB27-986F-46F2-AE0B-E329705228B5Q37708814-77A4162C-6817-4A29-A541-C4A468F626D5Q37709481-370607BC-AE08-4E01-8BAD-C5C585E6C626Q38148583-B974B8DF-6B20-4289-84DD-0BD16E2F594BQ38153446-2DBDACB4-4A47-4457-89A9-9ABAFE5D2856Q38542076-2A6A7850-9402-4E25-8B92-531C890AB8C9Q38688750-2AEEC287-1A28-4542-BFBF-DE88039319D1Q38829545-546C6C07-D688-480A-8E16-98F400ABFE3EQ38952088-11EE9EF0-9190-4FD1-BB41-7AB69B4CC565Q39281214-DD905F08-7841-4F36-9977-483DC06E467FQ41341914-90FF4C1C-3A92-4DDC-80F4-4037DBE175C3Q41396204-52525022-A048-4644-8DF9-B2761CEED526Q43555541-161206E8-0C7E-49D4-8D21-8192E95DF7A1Q44774245-A6CC05FB-6062-4ED9-8444-923ABBADBE9DQ45243918-652373C8-D75B-47F4-8DE3-D6A7DC8F992DQ47147399-CCECEC75-619A-435C-A51D-113FC20C4E03Q48083050-D973279C-28BC-4B5A-BEBF-987A3B4FBB70Q48132127-4401866D-8D50-408C-82BC-DB5011DE87EA
P2860
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Treating patients with EGFR-se ...... d line--is there a difference?
@en
type
label
Treating patients with EGFR-se ...... d line--is there a difference?
@en
prefLabel
Treating patients with EGFR-se ...... d line--is there a difference?
@en
P2093
P356
P1476
Treating patients with EGFR-se ...... d line--is there a difference?
@en
P2093
Jin-Ji Yang
Kwok-Chi Lam
P304
P356
10.1200/JCO.2012.43.0652
P407
P577
2013-02-11T00:00:00Z